Edgewise Therapeutics reported Q3 2026 results and dosed the first patient in its Phase 2 EQUINOX-HFpEF trial. Additionally, positive CIRRUS-HCM Part D results for EDG-7500 may support a Phase 3 trial initiation by year-end 2026, keeping the pipeline on target.